Michael Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Fu has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Annika Rosengren
Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden
4 shared publications - Erik Thunström
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden; Region Västra Götaland, Sahlgrenska University Hospital/Östra, Department of Medicine, Geriatrics and Emergency Medicine, Gothenburg, Sweden
4 shared publications Ulf Dahlström
Department of Cardiology, Linköping University, Linköping, Sweden
4 shared publicationsLars H. Lund
Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
3 shared publicationsAldina Pivodic
Advanced Process Network Control, Statistics in Life Science, Gothenburg 40530, Sweden
2 shared publications- Aldina Pivodic
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 11 (3) , 177-180
The 2026 ESC heart failure guidelines: advancing science while facilitating clinical implementation
The 2026 European Society of Cardiology (ESC) guidelines for the management of heart failure introduce a series of important changes intended to simplify classification, accelerate implementation of effective therapies, and shift care toward earlier prevention and intervention. Among the most notable changes are the incorporation of patients with mildly reduced left ventricular ejection fraction into the heart failure with reduced ejection fraction category, the replacement of the traditional concept of guideline-directed medical therapy with a three-tiered framework of foundational medical therapy, additional medical therapy, and guideline-directed interventional therapy, and greater emphasis on prevention through the formal use of stages A to D. The guidelines also favor the term “decompensated heart failure” over “acute heart failure,” reinforcing the concept that clinical deterioration often reflects an evolving process rather than an abrupt event. These changes provide a clearer and more actionable clinical pathway and emphasize rapid initiation of foundational therapies and timely referral for advanced heart failure care. At the same time, simplification may reduce phenotypic granularity, and some recommendations warrant continued discussion regarding the relationship between recommendation strength and supporting evidence. The Class I recommendation for mineralocorticoid receptor antagonists in symptomatic heart failure with preserved ejection fraction illustrates this tension, particularly given differences between steroidal and non-steroidal agents and across patient phenotypes. Overall, the 2026 ESC guidelines provide a pragmatic, forward-looking framework that may improve implementation and continuity of heart failure care. Their greatest impact, however, will depend not only on scientific rigor, but also on thoughtful interpretation, individualized application, and timely translation into everyday clinical practice.
- 1 July 2026
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 11 (3) , 177-180
Open AccessThe 2026 ESC heart failure guidelines: advancing science while facilitating clinical implementation
The 2026 European Society of Cardiology (ESC) guidelines for the management of heart failure introduce a series of important changes intended to simplify classification, accelerate implementation of effective therapies, and shift care toward earlier prevention and intervention. Among the most notable changes are the incorporation of patients with mildly reduced left ventricular ejection fraction into the heart failure with reduced ejection fraction category, the replacement of the traditional concept of guideline-directed medical therapy with a three-tiered framework of foundational medical therapy, additional medical therapy, and guideline-directed interventional therapy, and greater emphasis on prevention through the formal use of stages A to D. The guidelines also favor the term “decompensated heart failure” over “acute heart failure,” reinforcing the concept that clinical deterioration often reflects an evolving process rather than an abrupt event. These changes provide a clearer and more actionable clinical pathway and emphasize rapid initiation of foundational therapies and timely referral for advanced heart failure care. At the same time, simplification may reduce phenotypic granularity, and some recommendations warrant continued discussion regarding the relationship between recommendation strength and supporting evidence. The Class I recommendation for mineralocorticoid receptor antagonists in symptomatic heart failure with preserved ejection fraction illustrates this tension, particularly given differences between steroidal and non-steroidal agents and across patient phenotypes. Overall, the 2026 ESC guidelines provide a pragmatic, forward-looking framework that may improve implementation and continuity of heart failure care. Their greatest impact, however, will depend not only on scientific rigor, but also on thoughtful interpretation, individualized application, and timely translation into everyday clinical practice.
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 11 (1) , 5-6
Bridging traditions and evidence: Qiliqiangxin in the evolving landscape of heart failure therapy
- 1 January 2026
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 11 (1) , 5-6
Open AccessBridging traditions and evidence: Qiliqiangxin in the evolving landscape of heart failure therapy
- Open Access
Long-Term Prognosis and Early Clinical Predictors in Acute Myocarditis: Insights from a 10-year, Unselected Hospital Cohort
Background Acute myocarditis (AM) is an inflammatory cardiac condition with variable prognosis, ranging from complete recovery to progressive heart failure (HF) or death. While advances in diagnostics, such as high-sensitivity troponins and cardiac magnetic resonance imaging (CMR), have facilitated detection of milder cases, prognostic insights across unselected, real-world populations remain limited. Methods In this retrospective cohort study, we analyzed 471 consecutive patients hospitalized with a discharge diagnosis of AM between 2009 and 2019. Inclusion was based on clinical diagnosis. Baseline clinical features, laboratory data, and imaging results were extracted and systematically reviewed. The primary composite outcome comprised all-cause mortality, heart transplantation, use of mechanical circulatory support, new-onset HF, ventricular arrhythmias, and cardiac device implantation. Results The median age was 34 years, 32% were female. Chest pain was the predominant presenting symptom (87%), while ST-segment elevation was observed in 48% of cases. At admission, 24.2% of patients had hypokinesia on echocardiography, and 11.6% had a left ventricular ejection fraction (LVEF) Conclusions In this real-world, decade-long cohort, the majority of patients had favorable outcomes. However, a small subset experienced poor outcomes in both the short and long term, highlighting the need for early risk stratification and targeted management of high-risk individuals. What is new? This is one of the largest real-world cohorts (n = 471) of patients hospitalized with acute myocarditis (AM) diagnosed through clinical judgment, CMR, or EMB over a 10-year period. Unlike prior studies, inclusion was not limited to CMR-or biopsy-confirmed cases, offering a more representative clinical picture. Most patients (87.9%) had favorable long-term outcomes; early adverse events were significantly associated with: older age; heart failure signs at admission and regional hypokinesia. What are the clinical implications? Bedside clinical features, particularly heart failure symptoms and echocardiographic hypokinesia are powerful early predictors of poor prognosis and can guide triage and monitoring decisions. Patients without chest pain, or presenting with dyspnea, elevated NT-proBNP, and regional wall motion abnormalities, are at higher risk and may require closer follow-up. This study offers a more inclusive and practical understanding of AM prognosis and supports risk-adapted strategies in real-world cardiology.
Open AccessLong-Term Prognosis and Early Clinical Predictors in Acute Myocarditis: Insights from a 10-year, Unselected Hospital Cohort
Background Acute myocarditis (AM) is an inflammatory cardiac condition with variable prognosis, ranging from complete recovery to progressive heart failure (HF) or death. While advances in diagnostics, such as high-sensitivity troponins and cardiac magnetic resonance imaging (CMR), have facilitated detection of milder cases, prognostic insights across unselected, real-world populations remain limited. Methods In this retrospective cohort study, we analyzed 471 consecutive patients hospitalized with a discharge diagnosis of AM between 2009 and 2019. Inclusion was based on clinical diagnosis. Baseline clinical features, laboratory data, and imaging results were extracted and systematically reviewed. The primary composite outcome comprised all-cause mortality, heart transplantation, use of mechanical circulatory support, new-onset HF, ventricular arrhythmias, and cardiac device implantation. Results The median age was 34 years, 32% were female. Chest pain was the predominant presenting symptom (87%), while ST-segment elevation was observed in 48% of cases. At admission, 24.2% of patients had hypokinesia on echocardiography, and 11.6% had a left ventricular ejection fraction (LVEF) Conclusions In this real-world, decade-long cohort, the majority of patients had favorable outcomes. However, a small subset experienced poor outcomes in both the short and long term, highlighting the need for early risk stratification and targeted management of high-risk individuals. What is new? This is one of the largest real-world cohorts (n = 471) of patients hospitalized with acute myocarditis (AM) diagnosed through clinical judgment, CMR, or EMB over a 10-year period. Unlike prior studies, inclusion was not limited to CMR-or biopsy-confirmed cases, offering a more representative clinical picture. Most patients (87.9%) had favorable long-term outcomes; early adverse events were significantly associated with: older age; heart failure signs at admission and regional hypokinesia. What are the clinical implications? Bedside clinical features, particularly heart failure symptoms and echocardiographic hypokinesia are powerful early predictors of poor prognosis and can guide triage and monitoring decisions. Patients without chest pain, or presenting with dyspnea, elevated NT-proBNP, and regional wall motion abnormalities, are at higher risk and may require closer follow-up. This study offers a more inclusive and practical understanding of AM prognosis and supports risk-adapted strategies in real-world cardiology.
- Open Access
- 15 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (20) , e034891
Association Between Body Mass Index and Risk of Aortic Stenosis in Women in the Swedish Medical Birth Registry
Background: Overweight and obesity are increasing globally with aging, as are life expectancy and aging‐associated disorders, including calcific aortic stenosis (AS). Studies investigating the correlation between high body mass index (BMI) and AS are contradictory and inconclusive. This study examines a potential association between BMI and AS in women. Methods and Results: By linking the Swedish Medical Birth Register and the Swedish National Patient Register, we included women aged 18 to 55 years with a first childbirth from 1981 to 2020. Diagnosis of AS and comorbidities were defined according to the International Classification of Diseases ( ICD ) codes. The women were divided into groups on the basis of BMI. Cox proportional hazards regression models were used to investigate the difference in the risk of being diagnosed with AS, with reference BMI 20 to 2 . Among the 1 722 625 included women, the mean age was 28 years, and mean BMI was 24 kg/m 2 , with 21% being overweight (BMI 25 to 2 ) and 8.5% obese (BMI ≥30 kg/m 2 ). During median follow‐up of 19.5 years, 2488 women (0.14%) were diagnosed with AS. The age‐adjusted risk of being diagnosed with AS increased with higher BMI to 2.82 (95% CI, 2.44–3.25) times higher in women with BMI 30 to 2 , and to 3.72 (95% CI, 2.95–4.70) times higher in those with BMI ≥35 kg/m 2 . Similar results were found after excluding AS of rheumatic pathogenesis. Conclusions: An increase in BMI from its upper normal range was consistently and independently associated with the risk of developing AS in women.
- 15 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (20) , e034891
Open AccessAssociation Between Body Mass Index and Risk of Aortic Stenosis in Women in the Swedish Medical Birth Registry
Background: Overweight and obesity are increasing globally with aging, as are life expectancy and aging‐associated disorders, including calcific aortic stenosis (AS). Studies investigating the correlation between high body mass index (BMI) and AS are contradictory and inconclusive. This study examines a potential association between BMI and AS in women. Methods and Results: By linking the Swedish Medical Birth Register and the Swedish National Patient Register, we included women aged 18 to 55 years with a first childbirth from 1981 to 2020. Diagnosis of AS and comorbidities were defined according to the International Classification of Diseases ( ICD ) codes. The women were divided into groups on the basis of BMI. Cox proportional hazards regression models were used to investigate the difference in the risk of being diagnosed with AS, with reference BMI 20 to 2 . Among the 1 722 625 included women, the mean age was 28 years, and mean BMI was 24 kg/m 2 , with 21% being overweight (BMI 25 to 2 ) and 8.5% obese (BMI ≥30 kg/m 2 ). During median follow‐up of 19.5 years, 2488 women (0.14%) were diagnosed with AS. The age‐adjusted risk of being diagnosed with AS increased with higher BMI to 2.82 (95% CI, 2.44–3.25) times higher in women with BMI 30 to 2 , and to 3.72 (95% CI, 2.95–4.70) times higher in those with BMI ≥35 kg/m 2 . Similar results were found after excluding AS of rheumatic pathogenesis. Conclusions: An increase in BMI from its upper normal range was consistently and independently associated with the risk of developing AS in women.
- Open Access
- 1 January 2024
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 9 (1) , 12-22
Real-world effectiveness of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a retrospective, non-interventional cohort analysis
Background and purpose: Mineralocorticoid receptor antagonists (MRAs) have been shown in clinical trials to improve outcomes in heart failure with reduced ejection fraction (HFrEF). Yet, it is still uncertain how effective they are in real-world patients with HFrEF. This study aimed to investigate the association between MRAs and outcomes in the overall population and a propensity score-matched cohort, based on patient-level data from the Swedish Heart Failure Registry (SwedeHF). Methods: Patients diagnosed with HFrEF were included from the SwedeHF spanning from 2003 to 2020. Enrollment was based on medication dispensation within 3 months before and 6 months after the index date recorded in the register. Endpoints included all-cause mortality, cardiovascular death, and hospital re-admissions, tracked from the index date until censoring or occurrence of an event. Results: Of 47,103 patients identified through the SwedeHF with HFrEF, 22,368 individuals were not treated with MRA (referred to as MRA naive patients), 21,893 were treated with MRA at a dosage of 25 mg, and 1,423 were treated with MRA at 50 mg once daily. In the overall cohort, the administration of MRA at 25 mg was associated with modest reductions in the risk of all-cause mortality (hazard ratio: 0.92 [0.89–0.95], P < 0.0001) and cardiovascular death (hazard ratio: 0.93 [0.89–0.98], P < 0.01) compared to the MRA naive group. However, both dosages of MRA (25 and 50 mg) were associated with a slight increase in the risk of hospital re-admissions due to heart failure 10% compared to MRA naive patients. These findings were consistent when examining a propensity score-matched cohort. Interaction analysis showed a significantly improved survival rate for patients receiving MRA at 25 mg compared to MRA naive individuals, particularly among those with an estimated glomerular rate ≥30 mL/min/1.73 m2 across all patients and in those aged 70 years and above. Conclusions: The administration of MRA treatment at 25 mg once daily was linked to a modestly improved survival in a real-life HFrEF population, with even more pronounced benefits observed within a specific subgroup. This finding highlights the importance of personalized medicine in providing customized therapeutic advantages.
- 1 January 2024
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 9 (1) , 12-22
Open AccessReal-world effectiveness of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a retrospective, non-interventional cohort analysis
Background and purpose: Mineralocorticoid receptor antagonists (MRAs) have been shown in clinical trials to improve outcomes in heart failure with reduced ejection fraction (HFrEF). Yet, it is still uncertain how effective they are in real-world patients with HFrEF. This study aimed to investigate the association between MRAs and outcomes in the overall population and a propensity score-matched cohort, based on patient-level data from the Swedish Heart Failure Registry (SwedeHF). Methods: Patients diagnosed with HFrEF were included from the SwedeHF spanning from 2003 to 2020. Enrollment was based on medication dispensation within 3 months before and 6 months after the index date recorded in the register. Endpoints included all-cause mortality, cardiovascular death, and hospital re-admissions, tracked from the index date until censoring or occurrence of an event. Results: Of 47,103 patients identified through the SwedeHF with HFrEF, 22,368 individuals were not treated with MRA (referred to as MRA naive patients), 21,893 were treated with MRA at a dosage of 25 mg, and 1,423 were treated with MRA at 50 mg once daily. In the overall cohort, the administration of MRA at 25 mg was associated with modest reductions in the risk of all-cause mortality (hazard ratio: 0.92 [0.89–0.95], P < 0.0001) and cardiovascular death (hazard ratio: 0.93 [0.89–0.98], P < 0.01) compared to the MRA naive group. However, both dosages of MRA (25 and 50 mg) were associated with a slight increase in the risk of hospital re-admissions due to heart failure 10% compared to MRA naive patients. These findings were consistent when examining a propensity score-matched cohort. Interaction analysis showed a significantly improved survival rate for patients receiving MRA at 25 mg compared to MRA naive individuals, particularly among those with an estimated glomerular rate ≥30 mL/min/1.73 m2 across all patients and in those aged 70 years and above. Conclusions: The administration of MRA treatment at 25 mg once daily was linked to a modestly improved survival in a real-life HFrEF population, with even more pronounced benefits observed within a specific subgroup. This finding highlights the importance of personalized medicine in providing customized therapeutic advantages.
- Open Access
- 1 January 2024
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 9 (1) , 6-8
Enhancing implementation of evidence-based heart failure therapies in clinical practice: vital to modern medicine
- 1 January 2024
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 9 (1) , 6-8
Open AccessEnhancing implementation of evidence-based heart failure therapies in clinical practice: vital to modern medicine
- Open Access
- 27 September 2023
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 113 (12) , 1661-1669
Cumulative incidence and risk factors of myocardial infarction during 20 years of follow-up: comparing two cohorts of middle-aged men born 30 years apart
Objective: To study cumulative incidence and predictors of myocardial infarction (MI) in two random general population samples consisting of middle-aged Swedish men born 30 years apart. Method: Results from the “Study of Men Born In 1913” and the “Study of Men Born In 1943”, two longitudinal cohort studies performed in the same geographic area and using the same methodology were compared. Both cohorts were followed prospectively from 50 to 70 years of age. MI was defined as first myocardial infarction, fatal or non-fatal. Results: Men born in 1943 had a 34% lower cumulative risk of first MI [HR 0.66 (0.50–0.88), p = 0.0051] during follow-up as compared to men born in 1913. Interaction analysis showed that hypertension had a significantly higher impact on risk of MI in cohort 1943 than in cohort 1913 [HR 2.33 (95% CI 1.41–3.83)] and [HR 1.10 (0.74–1.62)], p = 0.0009 respectively. The population attributable risk for hypertension was 2.5-fold higher in the cohort of men born in 1943 as compared to men born in 1913, and diabetes mellitus and sedentary lifestyle attributed more to MI risk in cohort 1943 than in cohort 1913. On the contrary, smoking and total cholesterol have less attributable risk to MI in cohort 1943 than in cohort 1913. Conclusion: Despite declining incident MI and improved cardiovascular prevention in general, hypertension remains an increasingly important attributable risk factor to MI together with diabetes mellitus and sedentary lifestyle over time.
- 27 September 2023
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 113 (12) , 1661-1669
Open AccessCumulative incidence and risk factors of myocardial infarction during 20 years of follow-up: comparing two cohorts of middle-aged men born 30 years apart
Objective: To study cumulative incidence and predictors of myocardial infarction (MI) in two random general population samples consisting of middle-aged Swedish men born 30 years apart. Method: Results from the “Study of Men Born In 1913” and the “Study of Men Born In 1943”, two longitudinal cohort studies performed in the same geographic area and using the same methodology were compared. Both cohorts were followed prospectively from 50 to 70 years of age. MI was defined as first myocardial infarction, fatal or non-fatal. Results: Men born in 1943 had a 34% lower cumulative risk of first MI [HR 0.66 (0.50–0.88), p = 0.0051] during follow-up as compared to men born in 1913. Interaction analysis showed that hypertension had a significantly higher impact on risk of MI in cohort 1943 than in cohort 1913 [HR 2.33 (95% CI 1.41–3.83)] and [HR 1.10 (0.74–1.62)], p = 0.0009 respectively. The population attributable risk for hypertension was 2.5-fold higher in the cohort of men born in 1943 as compared to men born in 1913, and diabetes mellitus and sedentary lifestyle attributed more to MI risk in cohort 1943 than in cohort 1913. On the contrary, smoking and total cholesterol have less attributable risk to MI in cohort 1943 than in cohort 1913. Conclusion: Despite declining incident MI and improved cardiovascular prevention in general, hypertension remains an increasingly important attributable risk factor to MI together with diabetes mellitus and sedentary lifestyle over time.
- Open Access
- 29 November 2022
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 112 (1) , 167-174
Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
Aims: Sacubitril/valsartan is a first-in-class angiotensin receptor–neprilysin inhibitor (ARNI) with a class-1 guideline recommendation. We assessed the real-world effectiveness of ARNI versus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) on all-cause and cardiovascular (CV)-related mortality and hospitalizations in heart failure (HF) with reduced or mildly reduced ejection fraction (EF). Methods: Patient-level clinical, laboratory, drug dispensation, hospitalization, and mortality data were derived from the Swedish Heart Failure Registry (SwedeHF) and interlinked databases (1 April 2016–31 December 2020). Eligible ARNI:ACEi/ARB patients (n = 7275:24,604) had a left ventricular EF < 50%. Mortality and hospitalizations with ARNI (≤ 3 months pre-/post-1 April 2016 index [SwedeHF]; n = 1506) versus ACEi/ARB (≤ 3 months post-index; n = 17,108) were assessed using propensity score matching (1:1 ratio) with clinical variables, and sensitivity analysis (1:2/1:3 with, and 1:2 without clinical variables). Results: ARNI induced a 23% reduction in all-cause mortality versus ACEi/ARB (1:1 hazard ratio [HR; 95% confidence interval (CI)]: 0.77 [0.63–0.95], p = 0.013), and a non-significant 23% relative risk reduction in CV-related mortality (0.77 [0.54–1.09], p = 0.13), but no difference in all-cause or CV-related hospitalization (1.02 [0.91–1.13]; p = 0.76; 1.01 [0.91–1.15]; p = 0.84, respectively). Sensitivity analyses confirmed all-cause mortality was reduced for ARNI versus ACEi/ARB (HR 0.90 [95% CI 0.82–0.99], p = 0.026), but not CV-related mortality (HR 1.04 [95% CI 0.89–1.22], p = 0.63). Conclusions: In this nationwide real-world study including a population of patients with HF with reduced or mildly reduced EF, ARNI as part of guideline-led Swedish clinical practice was associated with a statistically significant relative risk reduction in all-cause mortality compared with ACEi/ARB.
- 29 November 2022
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 112 (1) , 167-174
Open AccessReal-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
Aims: Sacubitril/valsartan is a first-in-class angiotensin receptor–neprilysin inhibitor (ARNI) with a class-1 guideline recommendation. We assessed the real-world effectiveness of ARNI versus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) on all-cause and cardiovascular (CV)-related mortality and hospitalizations in heart failure (HF) with reduced or mildly reduced ejection fraction (EF). Methods: Patient-level clinical, laboratory, drug dispensation, hospitalization, and mortality data were derived from the Swedish Heart Failure Registry (SwedeHF) and interlinked databases (1 April 2016–31 December 2020). Eligible ARNI:ACEi/ARB patients (n = 7275:24,604) had a left ventricular EF < 50%. Mortality and hospitalizations with ARNI (≤ 3 months pre-/post-1 April 2016 index [SwedeHF]; n = 1506) versus ACEi/ARB (≤ 3 months post-index; n = 17,108) were assessed using propensity score matching (1:1 ratio) with clinical variables, and sensitivity analysis (1:2/1:3 with, and 1:2 without clinical variables). Results: ARNI induced a 23% reduction in all-cause mortality versus ACEi/ARB (1:1 hazard ratio [HR; 95% confidence interval (CI)]: 0.77 [0.63–0.95], p = 0.013), and a non-significant 23% relative risk reduction in CV-related mortality (0.77 [0.54–1.09], p = 0.13), but no difference in all-cause or CV-related hospitalization (1.02 [0.91–1.13]; p = 0.76; 1.01 [0.91–1.15]; p = 0.84, respectively). Sensitivity analyses confirmed all-cause mortality was reduced for ARNI versus ACEi/ARB (HR 0.90 [95% CI 0.82–0.99], p = 0.026), but not CV-related mortality (HR 1.04 [95% CI 0.89–1.22], p = 0.63). Conclusions: In this nationwide real-world study including a population of patients with HF with reduced or mildly reduced EF, ARNI as part of guideline-led Swedish clinical practice was associated with a statistically significant relative risk reduction in all-cause mortality compared with ACEi/ARB.
- Open Access
- 13 December 2021
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 23 (12) , e26794
Effects of Person-Centered Care Using a Digital Platform and Structured Telephone Support for People With Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: Randomized Controlled Trial
Background: Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) are characterized by severe symptom burden and common acute worsening episodes that often require hospitalization and affect prognosis. Although many studies have shown that person-centered care (PCC) increases self-efficacy in patients with chronic conditions, studies on patients with COPD and CHF treated in primary care and the effects of PCC on the risk of hospitalization in these patients are scarce. Objective: The aim of this study is to evaluate the effects of PCC through a combined digital platform and telephone support for people with COPD and CHF. Methods: A multicenter randomized trial was conducted from 2018 to 2020. A total of 222 patients were recruited from 9 primary care centers. Patients diagnosed with COPD, CHF, or both and with internet access were eligible. Participants were randomized into either usual care (112/222, 50.5%) or PCC combined with usual care (110/222, 49.5%). The intervention’s main component was a personal health plan cocreated by the participants and assigned health care professionals. The health care professionals called the participants in the intervention group and encouraged narration to establish a partnership using PCC communication skills. A digital platform was used as a communication tool. The primary end point, divided into 2 categories (improved and deteriorated or unchanged), was a composite score of change in general self-efficacy and hospitalization or death 6 months after randomization. Data from the intention-to-treat group at 3- and 6-month follow-ups were analyzed. In addition, a per-protocol analysis was conducted on the participants who used the intervention. Results: No significant differences were found in composite scores between the groups at the 3- and 6-month follow-ups. However, the per-protocol analysis of the 3-month follow-up revealed a significant difference in composite scores between the study groups (P=.047), although it was not maintained until the end of the 6-month follow-up (P=.24). This effect was driven by a change in general self-efficacy from baseline. Conclusions: PCC using a combined digital platform and structured telephone support seems to be an option to increase the short-term self-efficacy of people with COPD and CHF. This study adds to the knowledge of conceptual innovations in primary care to support patients with COPD and CHF. Trial Registration: ClinicalTrials.gov NCT03183817; http://clinicaltrials.gov/ct2/show/NCT03183817
- 13 December 2021
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 23 (12) , e26794
Open AccessEffects of Person-Centered Care Using a Digital Platform and Structured Telephone Support for People With Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: Randomized Controlled Trial
Background: Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) are characterized by severe symptom burden and common acute worsening episodes that often require hospitalization and affect prognosis. Although many studies have shown that person-centered care (PCC) increases self-efficacy in patients with chronic conditions, studies on patients with COPD and CHF treated in primary care and the effects of PCC on the risk of hospitalization in these patients are scarce. Objective: The aim of this study is to evaluate the effects of PCC through a combined digital platform and telephone support for people with COPD and CHF. Methods: A multicenter randomized trial was conducted from 2018 to 2020. A total of 222 patients were recruited from 9 primary care centers. Patients diagnosed with COPD, CHF, or both and with internet access were eligible. Participants were randomized into either usual care (112/222, 50.5%) or PCC combined with usual care (110/222, 49.5%). The intervention’s main component was a personal health plan cocreated by the participants and assigned health care professionals. The health care professionals called the participants in the intervention group and encouraged narration to establish a partnership using PCC communication skills. A digital platform was used as a communication tool. The primary end point, divided into 2 categories (improved and deteriorated or unchanged), was a composite score of change in general self-efficacy and hospitalization or death 6 months after randomization. Data from the intention-to-treat group at 3- and 6-month follow-ups were analyzed. In addition, a per-protocol analysis was conducted on the participants who used the intervention. Results: No significant differences were found in composite scores between the groups at the 3- and 6-month follow-ups. However, the per-protocol analysis of the 3-month follow-up revealed a significant difference in composite scores between the study groups (P=.047), although it was not maintained until the end of the 6-month follow-up (P=.24). This effect was driven by a change in general self-efficacy from baseline. Conclusions: PCC using a combined digital platform and structured telephone support seems to be an option to increase the short-term self-efficacy of people with COPD and CHF. This study adds to the knowledge of conceptual innovations in primary care to support patients with COPD and CHF. Trial Registration: ClinicalTrials.gov NCT03183817; http://clinicaltrials.gov/ct2/show/NCT03183817
- Open Access
- 27 November 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (1) , 555-563
Increasing Home-Time After a First Diagnosis of Heart Failure in Sweden, 20 Years Trends
Aims: This study was performed to compare trends in home-time for patients with heart failure (HF) between those of working age and those of retirement age in Sweden from 1992 to 2012. Methods and results: The National Inpatient Register (IPR) was used to identify all patients aged 18 to 84 years with a first hospitalization for HF in Sweden from 1992 to 2012. Information on date of death, comorbidities, and sociodemographic factors were collected from the Swedish National Register on Cause of Death, the IPR, and the longitudinal integration database for health insurance and labour market studies, respectively. The patients were divided into two groups according to their age: working age (<65 years) and retirement age (≥65 years). Follow-up was 4 years. In total, following exclusions, 388 775 patients aged 18 to 84 years who were alive 1 day after discharge from a first hospitalization for HF were included in the study. The working age group comprised 62 428 (16%) patients with a median age of 58 (interquartile range, 53–62) years and 31.2% women, and the retirement age group comprised 326 347 (84%) patients with a median age of 77 (interquartile range, 73–81) years and 47.4% women. Patients of working age had more home-time than patients of retirement age (83.8% vs. 68.2%, respectively), mainly because of their lower 4 year mortality rate (14.2% vs. 29.7%, respectively). Home-time increased over the study period for both age groups, but the increase levelled off for older women after 2007, most likely because of less reduction in mortality in older women than in the other groups. Conclusions: This nationwide study showed increasing home-time over the study period except for women of retirement age and older for whom the increase stalled after 2007, mainly because of a lower mortality reduction in this group. Efforts to improve patient-related outcome measures specifically targeted to this group may be warranted.
- 27 November 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (1) , 555-563
Open AccessIncreasing Home-Time After a First Diagnosis of Heart Failure in Sweden, 20 Years Trends
Aims: This study was performed to compare trends in home-time for patients with heart failure (HF) between those of working age and those of retirement age in Sweden from 1992 to 2012. Methods and results: The National Inpatient Register (IPR) was used to identify all patients aged 18 to 84 years with a first hospitalization for HF in Sweden from 1992 to 2012. Information on date of death, comorbidities, and sociodemographic factors were collected from the Swedish National Register on Cause of Death, the IPR, and the longitudinal integration database for health insurance and labour market studies, respectively. The patients were divided into two groups according to their age: working age (<65 years) and retirement age (≥65 years). Follow-up was 4 years. In total, following exclusions, 388 775 patients aged 18 to 84 years who were alive 1 day after discharge from a first hospitalization for HF were included in the study. The working age group comprised 62 428 (16%) patients with a median age of 58 (interquartile range, 53–62) years and 31.2% women, and the retirement age group comprised 326 347 (84%) patients with a median age of 77 (interquartile range, 73–81) years and 47.4% women. Patients of working age had more home-time than patients of retirement age (83.8% vs. 68.2%, respectively), mainly because of their lower 4 year mortality rate (14.2% vs. 29.7%, respectively). Home-time increased over the study period for both age groups, but the increase levelled off for older women after 2007, most likely because of less reduction in mortality in older women than in the other groups. Conclusions: This nationwide study showed increasing home-time over the study period except for women of retirement age and older for whom the increase stalled after 2007, mainly because of a lower mortality reduction in this group. Efforts to improve patient-related outcome measures specifically targeted to this group may be warranted.